Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
An Open-Label, Multicenter, Long Term Study to Evaluate the Safety, Tolerability and Efficacy of Fesoterodine in Patients With Overactive Bladder.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Chiba-ken
-
Inegeku, Chibashi, Chiba-ken, Japan
- Pfizer Investigational Site
-
-
Hyogo
-
Amagasaki-shi, Hyogo, Japan
- Pfizer Investigational Site
-
Kaibara-cho, tanba-shi, Hyogo, Japan
- Pfizer Investigational Site
-
-
Hyougo
-
Akashi-shi, Hyougo, Japan
- Pfizer Investigational Site
-
Chuou-ku, koube-shi, Hyougo, Japan
- Pfizer Investigational Site
-
Nishinomiya-shi, Hyougo, Japan
- Pfizer Investigational Site
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Japan
- Pfizer Investigational Site
-
-
Kanagawaken
-
Kawasakishi, Kanagawaken, Japan
- Pfizer Investigational Site
-
-
Nara
-
Nara-shi, Nara, Japan
- Pfizer Investigational Site
-
-
Osaka
-
Osaka-shi, Osaka, Japan
- Pfizer Investigational Site
-
-
Tokyo
-
Edogawa-ku, Tokyo, Japan
- Pfizer Investigational Site
-
Shibuya-ku, Tokyo, Japan
- Pfizer Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adult OAB patients who present with OAB symptoms, including micturitions >= 8 per day and urinary urgency episodes >=1 per day.
Exclusion Criteria:
- Patient has known hypersensitivity to the active substance (fesoterodine fumarate) or to peanut or soya or any of the excipients.
- Patient has a known neurological disease influencing bladder function.
- Patient has a complication of lower urinary tract pathology potentially responsible for urgency or incontinence, clinically relevant bladder outlet obstruction or pelvic organ prolapse.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Fesoterodine fumarate
|
4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Safety Measurement Based on Adverse Events (AEs), Vital Signs, Clinical Laboratory Test, 12-lead ECG and Residual Urine Volume
Tidsramme: 52 Weeks
|
The number of subjects who experienced AEs (all causality and treatment-related ) based on safety assessment during the study were summarized.
The severity and seriousness of treatment-emergent AEs as well as discontinuations, dose reductions and temporary discontinuations (DR/TD) due to treatment-emergent AEs were also summarized.
|
52 Weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 4, 8, 28 and 52
Tidsramme: Week 4, 8, 28 and 52
|
The number of UUI episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit. The mean number of UUI episodes per 24 hours was calculated as the total number of UUI episodes for valid diary days divided by the total number of valid diary days collected at that visit. Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline |
Week 4, 8, 28 and 52
|
|
Change From Baseline in Mean Number of Micturitions at Week 4, 8, 28 and 52
Tidsramme: Week 4, 8, 28 and 52
|
The number of micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit. The mean number of micturitions per 24 hours was calculated as the total number of micturitions for valid diary days divided by the total number of valid diary days collected at that visit. Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline |
Week 4, 8, 28 and 52
|
|
Change From Baseline in Mean Number of Urgency Episodes Per 24 Hours at Week 4, 8, 28 and 52
Tidsramme: Week 4, 8, 28 and 52
|
The number of urgency episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit. The mean number of urgency episodes per 24 hours was calculated as the total number of urgency episodes for valid diary days divided by the total number of valid diary days collected at that visit. Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline |
Week 4, 8, 28 and 52
|
|
Change From Baseline in Mean Incontinence Episodes Per 24 Hours at Week 4, 8, 28 and 52
Tidsramme: Week 4, 8, 28 and 52
|
The number of incontinence episodes was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit. The mean number of incontinence episodes per 24 hours was calculated as the total number of incontinence episodes for valid diary days divided by the total number of valid diary days collected at that visit. Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline |
Week 4, 8, 28 and 52
|
|
Change From Baseline in Number of Nighttime Micturitions Per 24 Hours at Week 4, 8, 28 and 52
Tidsramme: Week 4, 8, 28 and 52
|
The number of nighttime micturitions was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit. The mean number of nighttime micturitions per 24 hours was calculated as the total number of nighttime micturitions for valid diary days divided by the total number of valid diary days collected at that visit. Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline |
Week 4, 8, 28 and 52
|
|
Change From Baseline in Mean Voided Volume Per Micturition at Week 4, 8, 28 and 52
Tidsramme: Week 4, 8, 28 and 52
|
Voided volume per micturition was measured by the 3-day micturition diary completed for 3 consecutive days during the 7 days prior to each visit. The mean voided volume per micturitions was calculated as the total voided volume for valid diary days divided by the total number of valid diary days collected at that visit. Change: mean at Week 4, 8, 28 and 52 minus mean at Baseline |
Week 4, 8, 28 and 52
|
|
Change From Baseline in Score of King's Health Questionnaire (KHQ) at Week 28 and 52
Tidsramme: Week 28 and 52
|
KHQ was used to assess the impact of bladder problems on quality of life. The scores ranged from 0 to 100, where 0=best outcome/response and 100=worst outcome/response. A negative change indicates improvement. KHQ consists of the following domains:
Change: mean at Week 28 and 52 minus mean at Baseline |
Week 28 and 52
|
|
Change From Baseline in Score of Overactive Bladder Questionnaire (OAB-q) at Week 28 and 52
Tidsramme: Week 28 and 52
|
OAB-q was used to assess the extent of subjects who had been botehred by selected bladder symptoms and to assess the effect on their health-related quality of life (HRQL). OAB-q consists of the symptom bother score(SBS), the HRQL total score and subscale scores (Coping, Concern, Sleep and Social). The SBS ranges from 0 to 100, where 0=minimal severity and 100=greatest severity (negative change indicates improvement). The HRQL scores range from 0 to 100, where 0=worst outcome and 100=best outcome (positive change indicates improvement). Change: mean at Week 28 and 52 minus mean at baseline |
Week 28 and 52
|
|
The Number of Subjects Shifted in Patient Perception of Bladder Condition (PPBC) Responses From Baseilne to Week 28 and 52 Assessment and Its Percentage
Tidsramme: Week 28 and 52
|
The number of subjects whose perception of bladder condition improved at least by one grade on PPBC from baseline at Week 28 and 52. The PPBC was rated on a 6-point scale as follows:
|
Week 28 and 52
|
|
Change From Baseline in Grade of PPBC at Week 28 and 52
Tidsramme: Week 28 and 52
|
The PPBC assessment was rated on a 6-point scale as follows:
Change: mean at Week 28 and 52 minus mean at baseline A negative change indicates improvement. |
Week 28 and 52
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urologiske sygdomme
- Urinblæresygdomme
- Nedre urinvejssymptomer
- Urologiske manifestationer
- Urinblære, overaktiv
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Muskarine antagonister
- Kolinerge antagonister
- Kolinerge midler
- Urologiske midler
- Fesoterodin
Andre undersøgelses-id-numre
- A0221006
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .